letrozole has been researched along with Atypical Ductal Hyperplasia in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Primary endocrine therapy for ductal carcinoma in situ (DCIS) as a potential alternative to surgery has been understudied." | 2.94 | Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). ( Bedrosian, I; Caudle, A; Chen, YY; Dickson-Witmer, D; Duong, S; Esserman, L; Guenther, J; Hardman, T; Hendrix, LH; Hieken, T; Hoefer, R; Hudis, CA; Hwang, ES; Hylton, N; Hyslop, T; Krings, G; Lyss, AP; Marks, J; Ollila, DW; Price, E; Winer, E, 2020) |
| "Estrogens have important roles in ductal carcinoma in situ (DCIS) of the breast." | 1.39 | Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment. ( Amano, G; Amari, M; Ebata, A; Hirakawa, H; Ishida, T; Kakugawa, Y; Miki, Y; Mori, N; Nakamura, Y; Ohuchi, N; Sasano, H; Suzuki, T; Takagi, K; Watanabe, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hwang, ES | 1 |
| Hyslop, T | 1 |
| Hendrix, LH | 1 |
| Duong, S | 1 |
| Bedrosian, I | 1 |
| Price, E | 1 |
| Caudle, A | 1 |
| Hieken, T | 1 |
| Guenther, J | 1 |
| Hudis, CA | 1 |
| Winer, E | 1 |
| Lyss, AP | 1 |
| Dickson-Witmer, D | 1 |
| Hoefer, R | 1 |
| Ollila, DW | 1 |
| Hardman, T | 1 |
| Marks, J | 1 |
| Chen, YY | 1 |
| Krings, G | 1 |
| Esserman, L | 1 |
| Hylton, N | 1 |
| Lazzeroni, M | 1 |
| DeCensi, A | 1 |
| Gourd, E | 1 |
| Blok, EJ | 1 |
| Kroep, JR | 1 |
| Meershoek-Klein Kranenbarg, E | 1 |
| Duijm-de Carpentier, M | 1 |
| Putter, H | 1 |
| van den Bosch, J | 1 |
| Maartense, E | 1 |
| van Leeuwen-Stok, AE | 1 |
| Liefers, GJ | 1 |
| Nortier, JWR | 1 |
| Rutgers, EJT | 1 |
| van de Velde, CJH | 1 |
| Takagi, K | 1 |
| Ishida, T | 1 |
| Miki, Y | 1 |
| Hirakawa, H | 1 |
| Kakugawa, Y | 1 |
| Amano, G | 1 |
| Ebata, A | 1 |
| Mori, N | 1 |
| Nakamura, Y | 1 |
| Watanabe, M | 1 |
| Amari, M | 1 |
| Ohuchi, N | 1 |
| Sasano, H | 1 |
| Suzuki, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)[NCT01439711] | Phase 2 | 108 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in maximum diameter at 6-months based on mammographic measurement (MD6) will be estimated using the methods in Primary Outcome #1, but using the mammographic measurements instead. (NCT01439711)
Timeframe: 6-months
| Intervention | millimeters (Mean) |
|---|---|
| Letrozole + MRI | -3.31 |
Mean total MRI FTV change from baseline to month 3 (V3): For patients with more than one measureable lesion on the MRI, the sum over all measureable lesions on the MRI was calculated at each time point. V3 was calculated by subtracting the total MRI FTV measured (i.e. the sum over all lesions present with MRI FTV measurements) at 3 months from the total MRI FTV measured at baseline. For V3 the raw change in the volume will be calculated for each patient and a mean and 95% confidence interval will be constructed using two-sided t-tests. (NCT01439711)
Timeframe: up to 3 months from start of treatment
| Intervention | cubic centimeters (Mean) |
|---|---|
| Letrozole + MRI | -1.93 |
Mean total MRI FTV change from baseline to month 6 (V6): For patients with more than one measureable lesion on the MRI, the sum over all measureable lesions on the MRI was calculated at each time point. V6 was calculated by subtracting the total MRI FTV measured at 6 months from the total MRI FTV measured at baseline. For V6 the raw change in the volume will be calculated for each patient and a mean and 95% confidence interval will be constructed using two-sided t-tests. (NCT01439711)
Timeframe: up to 6 months from start of treatment
| Intervention | cubic centimeters (Mean) |
|---|---|
| Letrozole + MRI | -1.82 |
To ascertain the change in maximum tumor diameter from baseline to 3 months (D3) the same methods as in Primary outcome #1 will be used but on diameter instead of volume. For patients with more than one lesion longest diameter measurement, the sum of all lesion longest diameter measurements was calculated. (NCT01439711)
Timeframe: 3-months
| Intervention | millimeters (Mean) |
|---|---|
| Letrozole + MRI | -10.3 |
Mean total MRI tumor diameter change from baseline to month 6: To ascertain the change in maximum tumor diameter from baseline to 6 months (D6) the same methods as in Primary Outcome #2 will be used but on diameter instead of volume. (NCT01439711)
Timeframe: 6 months
| Intervention | millimeters (Mean) |
|---|---|
| Letrozole + MRI | -16.66 |
To ascertain the change in maximum tumor diameter from baseline to 6 months (D6) the same methods as in Primary outcome #2 will be used but on diameter instead of volume. For patients with more than one lesion longest diameter measurement, the sum of all lesion longest diameter measurements was calculated. (NCT01439711)
Timeframe: 6 months
| Intervention | millimeters (Mean) |
|---|---|
| Letrozole + MRI | -16.66 |
The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. The percentage of patients with a maximum grade 3 or higher adverse event at least possibly related to the study treatment are reported below. (NCT01439711)
Timeframe: Up to 6 months post surgery
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Allergic reaction | Cholesterol high | Gastrointestinal disorder | Hot flashes | |
| Letrozole + MRI | 31 | 7 | 2 | 1 |
Rate of Mastectomy will be estimated as the number of mastectomies divided by the number of surgeries. A 95% confidence interval will be constructed using exact binomial methods. Rate of Lumpectomy will be estimated as the number of lumpectomies divided by the number of surgeries. A 95% confidence interval will be constructed using exact binomial methods. (NCT01439711)
Timeframe: up to 6 months
| Intervention | percentage of surgeries (Number) | |
|---|---|---|
| Rate of Mastectomy | Rate of Lumpectomy | |
| Letrozole + MRI | 7 | 93 |
2 trials available for letrozole and Atypical Ductal Hyperplasia
| Article | Year |
|---|---|
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; | 2020 |
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcin | 2018 |
4 other studies available for letrozole and Atypical Ductal Hyperplasia
| Article | Year |
|---|---|
De-Escalating Treatment of Low-Risk Breast Ductal Carcinoma In Situ.
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Humans; Letroz | 2020 |
Preoperative endocrine therapy for ductal carcinoma in situ.
Topics: Carcinoma, Intraductal, Noninfiltrating; Estrogens; Humans; Letrozole; Mastectomy, Segmental; Postme | 2020 |
Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment.
Topics: Aged; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Es | 2013 |
NCCN Guideline update: Breast Cancer Version 1.2004.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2004 |